To test the effects of Rosuvastatin treatment on the outcome of prostate cancer, we monitored the levels of PSA, CAV1 and EGFR at baseline, after 3 and 6 months in statin and non-statin users PC patients. Here, KLK3 is linked to pachyonychia congenita.